文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

治疗性随机对照试验中快速改善的ARDS

Rapidly Improving ARDS in Therapeutic Randomized Controlled Trials.
PubMed 文献 · Chest · 2018-10-22
一句话结论快速改善的ARDS(主要定义为早期拔管)在ARDS网络试验中占10.5%且随时间增加,60天死亡率10.2% vs 26.3%,纳入此类患者可能影响试验预后富集。

该研究对六项ARDS网络随机对照试验的患者水平数据进行二次分析,将快速改善的ARDS定义为入组后第一个研究日拔管或PaO2:FIO2>300,并与ARDS>1天对比。快速改善的ARDS患病率为10.5%(458/4361),在最近三项试验中为13.9%(265/1909)。快速改善的ARDS患者基线病情严重程度更低,60天死亡率10.2% vs 26.3%(P<.0001)。筛查时PaO2:FIO2、筛查至入组期间PaO2:FIO2变化、血管升压药使用、入组时FIO2和血清胆红素水平是有用的预测变量。作者认为纳入快速改善的ARDS患者可能负面影响预后富集并导致治疗性试验失败。

要点

  • 快速改善的ARDS定义为入组后第一个研究日拔管或PaO2:FIO2>300,在六项ARDS网络试验中患病率10.5%(458/4361)。
  • 快速改善的ARDS患者60天死亡率10.2% vs ARDS>1天26.3%(P<.0001),预后显著更好。
  • 在最近三项试验中,快速改善的ARDS患病率为13.9%(265/1909),其中10.3%(197/1909)在第一个研究日拔管。
  • 筛查时PaO2:FIO2、筛查至入组期间PaO2:FIO2变化、血管升压药使用、入组时FIO2和血清胆红素水平是有用的预测变量。
  • 作者认为纳入快速改善的ARDS患者可能负面影响预后富集并导致治疗性试验失败。

适用人群与场景

  • 六项ARDS网络随机对照试验中符合ARDS标准的成人患者。
  • 研究场景为随机对照试验入组后第一个研究日。

诊断标准与关键阈值

  • 快速改善的ARDS定义为入组后第一个研究日拔管或PaO2:FIO2>300。
  • 对照定义为ARDS>1天。

研究设计与关键结果

  • 研究类型为对六项ARDS网络随机对照试验患者水平数据的二次分析,样本量4361例。
  • 快速改善的ARDS患病率为10.5%(458/4361),且随时间增加。
  • 在最近三项试验的1909例患者中,197例(10.3%)在第一个研究日拔管,总计265例(13.9%)为快速改善的ARDS。
  • 快速改善的ARDS患者基线病情严重程度更低,60天死亡率10.2% vs ARDS>1天26.3%(P<.0001)。
  • 筛查时PaO2:FIO2、筛查至入组期间PaO2:FIO2变化、血管升压药使用、入组时FIO2和血清胆红素水平是有用的预测变量。

证据类型、等级与局限

  • 证据类型:对六项随机对照试验的二次分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为纳入快速改善的ARDS患者可能负面影响预后富集并导致治疗性试验失败。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Observational studies suggest that some patients meeting criteria for ARDS no longer fulfill the oxygenation criterion early in the course of their illness. This subphenotype of rapidly improving ARDS has not been well characterized. We attempted to assess the prevalence, characteristics, and outcomes of rapidly improving ARDS and to identify which variables are useful to predict it.

METHODS: A secondary analysis was performed of patient level data from six ARDS Network randomized controlled trials. We defined rapidly improving ARDS, contrasted with ARDS > 1 day, as extubation or a Pao2 to Fio2 ratio (Pao2:Fio2) > 300 on the first study day following enrollment.

RESULTS: The prevalence of rapidly improving ARDS was 10.5% (458 of 4,361 patients) and increased over time. Of the 1,909 patients enrolled in the three most recently published trials, 197 (10.3%) were extubated on the first study day, and 265 (13.9%) in total had rapidly improving ARDS. Patients with rapidly improving ARDS had lower baseline severity of illness and lower 60-day mortality (10.2% vs 26.3%; P < .0001) than ARDS > 1 day. Pao2:Fio2 at screening, change in Pao2:Fio2 from screening to enrollment, use of vasopressor agents, Fio2 at enrollment, and serum bilirubin levels were useful predictive variables.

CONCLUSIONS: Rapidly improving ARDS, mostly defined by early extubation, is an increasingly prevalent and distinct subphenotype, associated with better outcomes than ARDS > 1 day. Enrollment of patients with rapidly improving ARDS may negatively affect the prognostic enrichment and contribute to the failure of therapeutic trials.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Schenck EJ, Oromendia C, Torres LK, et al. Rapidly Improving ARDS in Therapeutic Randomized Controlled Trials. Chest. 2018. PMID: 30359616. doi:10.1016/j.chest.2018.09.031

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。